Please assess the completion status of the following clinical trial:

Trial Title: Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological assessed diagnosis of non-Hodgkin's lymphoma.~* Diagnostic sample obtained by stereotactic or surgical biopsy, Cerebrospinal Fluid (CSF) cytology examination or vitrectomy.~* Disease exclusively localized into the central nervous system, CSF, cranial nerves or eyes.~* At least one measurable lesion.~* Previously untreated patients (previous or ongoing steroid therapy admitted).~* Age 18-65 years (with ECOG Performance Status 0-3) or 66-70 (with ECOG Performance Status 0-2).~* Adequate bone marrow, renal, cardiac, and hepatic function.~* Sexually active patients of childbearing potential agreeing in implementing adequate contraceptive measures during study participation.~* Absence of any familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.~* Patient-signed informed consent obtained before registration.~Exclusion Criteria:~* Patients with lymphomatous lesions outside the CNS.~* Patients with a previous non-Hodgkin lymphoma at any time.~* Previous or concurrent malignancies with the exception of surgically cured carcinoma in-situ of the cervix, carcinoma of the skin or other cancers without evidence of disease at least from 5 years.~* HBsAg and HCV positivity.~* HIV infection, previous organ transplantation or other clinically evident form of immunodeficiency.~* Concurrent treatment with other experimental drugs.~* Concurrent Pregnancy or lactation.~* Patients not agreeing to take adequate contraceptive measures during the study.~* Symptomatic coronary artery disease, cardiac arrhythmias uncontrolled with medication or myocardial infarction within the last 6 months (New York Heart Association Class III or IV heart disease).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MTX+ AraC (Type: EXPERIMENTAL): Arm A Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3
- Ara-C +Rituximab (Type: EXPERIMENTAL): Arm B Rituximab 375 mg/m2 conventional infusion d -5 \& 0 Methotrexate 3.5 g/m2 0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3
- Ara-C + rituximab+thiotepa (Type: EXPERIMENTAL): Arm C Rituximab 375 mg/m2 conventional infusion d -5 \& 0 Methotrexate 3.5 g/m2 0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3 Thiotepa 30 mg/m2 30 min. Infusion d 4
- WBRT 36 Gy +/- boost 9 Gy (Type: EXPERIMENTAL): ARM D: WBRT with 36 Gy in the case of CR to primary chemotherapy or the same WBRT dose followed by a tumor-bed boost of 9 Gy with 1-2 cm of margin surrounding enhanced residual lesion (total tumor-bed dose 45 Gy) in patients who achieved a PR or SD after primary chemotherapy. Photons of 4-10 Mev, 180 cGy per day, 5 weekly fractions.
- BCNU + Thiotepa + APBSCT (Type: EXPERIMENTAL): Arm E BCNU 400 mg/m2 in 500 ml saline sol 1-hr inf. day -6 Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf. every 12 hrs days -5 \& -4 Reinfusion of PBSC ≥5 x 106 CD34+ cells/kg day 0

Based on this trial design, predict the completion outcome and termination type (if applicable).